All you need to know about Steatotic Liver Disease! @TheLancet Seminar on SLD👇 A clinician-centered guide covering all from epidemiology, nomenclature, natural history, diagnosis and treatment to healthcare pathways. https://t.co/KoQW5DPTNQ #ManolisTsochatzis @FrancqueSven

Would you like to host an EASL School in 2027, in your European institution? Please share your ideas by completing and returning the application by 26 October. Read more: https://t.co/0jLkxeTHko @FrancqueSven @DebbieShawcros1 #LiverTwitter #LiverX

In patients w/ #Cirrhosis 📈#PortalHypertension #CSPH and 🔥#SystemicInflammation #SI coexist and drive both 🕸️#Liver disease progression and 🫀🫘🧠🫁 extrahepatic #organ pathology #Pathomechanistic #Phenotypes of #Cirrhosis 📕read @NatRevGastroHep 🔗 https://t.co/dyg6Sc4H2H

@BavenoCoop Baveno VIII consensus 27-28 MARCH 2026 secure your spot ⏩ https://t.co/HVWYzPUFRm @EASLnews @AASLDtweets @APASLnews @INASL_Liver

2 important messages that you must hear 👂 1. 1/3 of the globe has Steatotic Liver Disease #SLD. A metabolic disease that is 100% preventable. 2. Every 2 mins someone unnecessarily dies of viral hepatitis @EASLnews are at #UNGA80 in NYC championing liver disease @SagiZelber

MetALD associated with a higher risk of liver-related events, HCC, and extrahepatic cancers than MASLD, whereas all-cause mortality, extrahepatic cancer-related mortality, and cardiovascular events seem similar between the two conditions. https://t.co/PCdUyXbnub

Very good question @nagachalasani in this recent comprehensive review on PEth we tried to capture and explain the biology and pitfalls. https://t.co/2dvj6n1tmV

In ~3,000 individuals at risk of SLD: 🔍 39% of MASLD (by self-report) could be reclassified as MetALD (>20 ng/mL) or ALD (>200 ng/mL) using PEth ��� Triangulating with self-report, AUDIT-C and PEth refines SLD subclassification ✅ ⚖️ 40% of SLD cases: PEth seems redundant

Very happy to see many new member registrations to @BavenoCoop every month - it seems like the hepatology community is eagerly looking forward to #BavenoVIII consensus on #cirrhosis & #portalhypertension 🔗 https://t.co/ZGGyqbTXK1 @EASLnews @AASLDtweets @APASLnews @INASL_Liver

🍷 ➡️🥦🏃‍♀️ A large new study in the @JHepatology has found that a healthy #diet and regular #physicalactivity lower the risk of liver-related death across all drinking patterns, including heavy and binge drinking. 🏋️‍♀️🥗The findings highlight the importance of considering

🧩The EASL #SLDSummit 2026 (26–28 February, Budapest) will bring together experts and early-career researchers to explore the latest in steatotic liver disease, from prevention and diagnostics to innovative therapies and patient care. 🔎 Don’t miss the opening session: The

EASL is deeply saddened to share the news of the passing of Professor Michael P. Manns (1951–2025). A visionary leader in hepatology, Professor Manns shaped the field through his pioneering research in viral hepatitis, autoimmune liver diseases, transplantation and regenerative

@AleksanderKrag delivering the Datta lecture @INASL_Liver meeting on the role of #biomarkers in #alcohol related #liver disease @EASLnews @EASLedu @ajay_duseja #liverX

@INASL_Liver DV Datta Oration by @AleksanderKrag during 33rd Annual @INASL_Liver Conference at Chandigarh. Brilliant Oration on #ALD @EASLnews @AASLDtweets @APASLnews @AlcoholChangeUK @ajay_duseja

INASL-2025 Chandigarh First day begins with - Single Theme Symposium on MASLD @ajay_duseja @marurinella @AleksanderKrag @GSzaboMD @shivaramsingh @EASLnews @AASLDtweets

New guidance on using Phosphatidylethanol (PEth) as a biomarker for alcohol use over the past 2–4 weeks. PEth complements self-reported alcohol intake and AUDIT scores, 👉classifying patients within the spectrum of Steatotic liver disease! https://t.co/HdQf5MATNY

Collaborative Study @EASLnews 🇦🇹AT🇩🇰DE🇮🇹IT researchers have shown that the prognosis of #Patients wtih #Cirrhosis #Complications depends on the pattern of #acute (AD) or #nonacute (NAD) #Decompensation @AleksanderKrag @MedUni_Wien et al. https://t.co/jgfXxDeloK

The 2025 EASL #SLDsummit content is now available on demand is now accessible on demand for all users with a MyEASL account. Re-discover the sessions and ePosters on EASL Campus! 🔗 https://t.co/2gk5XrMkCw #LiverX #LiverTwitter

EASL joins the global hepatology community in mourning the passing of Prof. Jaime Bosch, a visionary clinician-scientist, educator, and leader whose legacy has shaped our field over the past five decades. From pioneering research in portal hypertension to mentoring generations

New Review - Screening for advanced steatotic liver disease https://t.co/YaKj6AKVKM @AleksanderKrag #LiverTwitter #MedTwitter

To Screen—or not to screen for for advanced steatotic liver disease? Our new @LancetGastroHep review re-examines Wilson & Jungner (1968), weighs today’s evidence, and proposes 2025 screening criteria @Stine_Johansen_ https://t.co/kooeWLGuOe